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Abstract
Background: We conducted a prospective study in a cohort of short-term travelers assessing the incidence rate of anti-
circumsporozoite seroconversion, adherence to chemoprophylaxis, symptoms of malaria during travel, and malaria
treatment abroad.
Methods: Adults were recruited from the travel clinic of the Public Health Service Amsterdam. They kept a structured daily
travel diary and donated blood samples before and after travel. Blood samples were serologically tested for the presence of
Plasmodium falciparum anti-circumsporozoite antibodies.
Results: Overall, the incidence rate (IR) of anti-circumsporozoite seroconversion was 0.8 per 100 person-months. Of 945
travelers, 620 (66%) visited high-endemic areas and were advised about both chemoprophylaxis and preventive measures
against mosquito bites. Most subjects (520/620 = 84%) took at least 75% of recommended prophylaxis during travel. Travel
to Africa, use of mefloquine, travel duration of 14–29 days in endemic areas, and concurrent use of DEET (N,N-diethyl-meta-
toluamide) were associated with good adherence practices. Four travelers without fever seroconverted, becoming anti-
circumsporozoite antibody-positive. All four had been adherent to chemoprophylaxis; two visited Africa, one Suriname, one
India. Ten subjects with fever were tested for malaria while abroad and of these, three received treatment. All three were
adherent to chemoprophylaxis and tested negative for anti-circumsporozoite antibodies.
Conclusion: Travel to Africa, using mefloquine, travel duration of 14–29 days in endemic areas, and use of DEET were
associated with good adherence to chemoprophylaxis. The combination of chemoprophylaxis and other preventive
measures were sufficient to protect seroconverting travelers from clinical malaria. Travelers who were treated for malaria
abroad did not seroconvert.
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Introduction
Half the world’s population is at risk of malaria [1,2]. An
estimated 216 million malaria cases, and 655,000 deaths, occurred
in 2010, mostly among the local population in malaria-endemic
regions [2]. Malaria also is a threat to the approximately 80–90
million travelers who visit the 106 endemic countries annually.
Travelers can protect themselves against malaria by using
antimalarial chemoprophylaxis and preventive measures against
mosquito bites. Recommendations for these preventive measures
are based on the anticipated infection rate and drug resistance
in Plasmodium falciparum [3–5], and differ by country.
Risk estimates for malaria infection among travelers from
nonendemic countries are usually based on transmission rates in
endemic populations and reports of infections in returned tourists.
Neither estimate correlates well with the risk for travelers [6,7].
Studies that estimate incidence based on these reports lack
information on how many travelers were protected by chemopro-
phylaxis and how many were treated for malaria abroad. They
are, however, valid to estimate trends. In the Netherlands, the
incidence of imported falciparum malaria among travelers declined
from 10.0/10,000 in the year 2000 to 3.4/10,000 travelers in
2007, whereas the proportion of travelers who did not use
chemoprophylaxis rose from 47% to 52% [8]. Since most of the
malaria cases occur in travelers who fail to use – or adhere to – the
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appropriate chemoprophylaxis [5,9–11], adherence to chemopro-
phylaxis is associated with protection against malaria. Prospective
studies among travelers are more valid to estimate risks [12]. Most
prospective studies are incomplete in their assessment of adher-
ence to chemoprophylaxis combined with serological testing for P.
falciparum infection [13–20]; in fact there is only one study, from
1991–1992, which examined both adherence to chemoprophylaxis
in relation to serological testing.
In order to contribute to a more definitive assessment of risks for
travelers, we conducted a comprehensive prospective study as to
the incidence rate of Plasmodium falciparum anti-circumsporozoite
seroconversion, adherence to chemoprophylaxis, symptoms of
malaria during travel, and malaria treatment abroad.
Methods
Ethics Statement
Study protocol was approved by the Medical Ethics Committee
of the Academic Medical Center Amsterdam (MEC 06/016).
Participants were included only with informed and written
consent.
Study Population
A prospective study was performed among persons attending
the travel clinic of the Public Health Service Amsterdam from
October 2006 to October 2007. All persons 18 years and older
were eligible if they were planning to travel for 1 to 13 weeks to
one or more malaria-endemic countries. Countries were grouped
in continents according to the composition of macro geographical
(continental) regions described by the United Nations Statistics
Division [21]. All participants were seen by a doctor or nurse
specialized in travel medicine. Based on Dutch national guidelines
for travelers’ health advice [22], participants traveling to low-risk
malaria-endemic areas (‘low-endemic areas’) were advised about
strict preventive measures against mosquito bites without chemo-
prophylaxis; participants traveling to intermediate- and/or high-
risk malaria-endemic areas (‘high-endemic areas’), were advised
about strict preventive measures against mosquito bites and
antimalarial chemoprophylaxis. Depending on travel destination
and travelers’ characteristics, atovaquone-proguanil, mefloquine,
doxycycline, or proguanil were recommended in the Netherlands
as chemoprophylaxis against infection with P. falciparum malaria
[22]. Travelers taking mefloquine were advised to start 3 weeks
Table 1. Characteristics of a prospective cohort of short-term travelers from the Netherlands who visited a malaria-endemic area,
October 2006–October 2007.
Travelers
No. travelers High-endemic areaa Low-endemic areab
Total 945 620 325
Sex
Male 400 42% 265 43% 135 42%
Female 545 58% 355 57% 190 58%
Age group, years
18–30 312 33% 207 33% 105 32%
31–45 304 32% 197 32% 107 33%
46–59 223 24% 155 25% 68 21%
./ = 60 106 11% 61 10% 45 14%
Country of birth
Western country 879 93% 581 94% 298 92%
Non-Western country 66 7% 39 6% 27 8%
Primary purpose of travel
Tourism 815 86% 519 84% 296 91%
Visiting friends and/or relatives 59 6% 42 7% 17 5%
Work or education 71 8% 59 10% 12 4%
Previous travel to a tropical/subtropical country
0 162 17% 91 15% 71 22%
1–6 times 546 58% 357 58% 189 58%
6 times or more 237 25% 172 28% 65 20%
Length of stay in endemic area
,/ = 13 days 529 56% 302 49% 227 70%
14–28 days 333 35% 249 40% 84 26%
./ = 29 days 83 9% 69 11% 14 4%
Travel destination
Africa 285 30% 279 45% 6 2%
Asia 454 48% 202 33% 252 78%
Latin America 206 22% 139 22% 67 21%
doi:10.1371/journal.pone.0056863.t001
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prior to arrival in high-endemic areas, in case of atovaquone-
proguanil one day. Travelers taking proguanil or doxycycline start
on the day of arrival. Travelers were advised to continue
mefloquine, proguanil, and doxycycline 4 weeks after leaving
high-endemic areas, and atovaquone-proguanil for 7 days.
Participants received a prescription for the appropriate antima-
larial chemoprophylaxis, oral and written information about
malaria, the use of chemoprophylaxis, and preventive measures
against mosquito bites.
Survey Methods
A standard questionnaire in Dutch or English was used before
departure to collect data on sociodemographics, travel history, and
purpose of travel (tourism, work or education, or visiting friends
Table 2. Determinants for 75% adherence to malaria chemoprophylaxis during travel among a prospective cohort of 620 travelers
from the Netherlands to high-endemic areas, October 2006–October 2007.
Total Adherenta
OR, Univariable
analysis, (95% CI) p-value
OR, Multivariable
analysisb, (95% CI)p-value
Total 620 520 84%
Sex
Male 265 43% 222 84% 1.00 0.955
Female 355 57% 298 84% 1.01 (0.66–1.56)
Age group, years
18–30 207 33% 169 82% 1.00 0.577
31–45 197 32% 164 83% 1.12 (0.67–1.87)
46–59 155 25% 134 86% 1.44 (0.80–2.56)
./ = 60 61 10% 53 87% 1.49 (0.65–3.39)
Country of birth
Western country 581 94% 486 84% 1.00 0.563
Non-Western country 39 6% 34 87% 1.33 (0.51–3.49)
Primary purpose of travel
Tourism 519 84% 432 83% 1.00 0.610
Visiting friends and/or relatives 42 7% 37 88% 1.49 (0.57–3.90)
Work or education 59 10% 51 86% 1.28 (0.59–2.80)
Previous travel to a (sub)tropical country
0 91 15% 77 85% 1.00 0.740
1–6 times 357 58% 296 83% 0.88 (0.47–1.66)
6 times or more 172 28% 147 85% 1.07 (0.53–2.17)
Length of stay in endemic area
#13 days 302 49% 237 78% 1.00 ,0.001 1.00 0.015
14–28 days 249 40% 227 91% 2.83 (1.69–4.74) 2.15 (1.21–3.81)
$29 days 69 11% 56 81% 1.18 (0.61–2.29) 0.87 (0.40–1.88)
Travel destination
Asia 202 33% 153 76% 1.00 ,0.001 1.00 ,0.001
Africa 279 45% 259 93% 4.15 (2.38–7.24) 3.53 (1.91–6.50)
Latin America 139 22% 108 78% 1.12 (0.67–1.86) 1.29 (0.75–2.21)
Type of chemoprophylaxis
Atovaquon-proguanil 449 72% 374 83% 1.00 0.009 1.00 0.071
Mefloquine 70 11% 68 97% 6.82 (1.64–28.43) 5.28 (1.20–23.13)
Proguanil 91 15% 68 75% 0.59 (0.35–1.01) 0.89 (0.47–1.67)
Other 10 2% 10 100%
Use of DEET, percentage
No 88 14% 65 74% 1.00 0.020 1.00 0.013
#25% 75 12% 60 80% 1.42 (0.68–2.96) 1.47 (0.66–3.27)
26–50% 103 17% 89 86% 2.25 (1.08–4.70) 2.18 (0.99–4.81)
51–75% 88 14% 81 92% 4.10 (1.65–10.14) 4.70 (1.82–12.14)
.75% 266 43% 225 85% 1.94 (1.09–3.47) 2.24 (1.20–4.20)
bIn the multivariable analysis the variable ‘type of chemoprophylaxis’ was included without the category ‘other’ because of 100% compliance, so multivariable analysis
was done with 610 travelers.
doi:10.1371/journal.pone.0056863.t002
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and/or relatives [VFR]). Participants were given a thermometer
and were asked to take their temperature if they felt feverish. They
were also asked to keep a structured travel diary, recording
itinerary, use of antimalarial chemoprophylaxis, use of preventive
measures against mosquito bites such as a mosquito net and/or an
insect repellent containing N,N-diethyl-meta-toluamide (DEET)
and/or sleeping in air conditioned rooms, signs of disease (fever),
doctor visits, and (self)treatment. Participants made daily diary
entries from the day they arrived at their destination to 2 weeks
after their return, to encompass the incubation period of
Plasmodium falciparum malaria and to register adherence to
chemoprophylaxis after return. After travel, a nurse checked the
diary in the presence of the participant. Participants were then
asked if they had taken the advised chemoprophylaxis prior to
travel – if applicable.
Case Definitions
The number of days spent in malaria-endemic areas was
defined as ‘exposure time’. Participants were considered ‘adherent’
to chemoprophylaxis if they took at least 75% of their
recommended tablets as prescribed during their stay in high-
endemic areas. Adherence before and after travel were separately
described. The use of DEET, use of a mosquito net, and sleeping
in an air-conditioned room were quantified in percentages by
dividing the number of days the preventive measure was used by
the number of days spent in a malaria-endemic area; and we
dichotomized these variables by using the mean of this proportion
in the total study population as the cut-off. Fever was self-reported
(feeling feverish or thermometer confirmed fever with a temper-
ature of 38uC or higher) starting 1 week after arriving in a malaria-
endemic area.
Laboratory Methods
Before departure and 2 to 6 weeks after return, participants
donated venous blood samples for serology. All blood samples
were immediately stored at 6uC. Blood samples for serologic
testing were centrifuged (Hettich Rotixa 50 S, see APP/407:
program 1, 10 min. 3000 rpm (210 g)) and frozen at 280uC
within 24 hours until use. The CSP-ELISA (circumsporozoite
protein enzyme-linked immunosorbent assay) was used to test
for the presence of P. falciparum anti-circumsporozoite antibodies
according to standard protocols [23]. The optical density (OD)
was read at 450 nm (reference filter 620 nm). Positive-control
pooled plasma samples from Tanzanian individuals and
negative-control plasma samples from Dutch individuals were
included in each plate. The threshold for positivity for anti-
circumsporozoite antibodies was calculated as the mean OD of
the 7 negative control plasma samples plus 3 standard
deviations. If the (OD) in serum samples after travel tested
positive and showed a $2-fold increase compared to the OD
value pretravel, these were defined as anti-circumsporozoite
antibody seroconversion. This anti-circumsporozoite antibody
seroconversion was considered indicative of exposure to P.
falciparum during present travel.
Data Analysis
Data analysis was performed with SPSS version 19.0.0.1 (2010,
IBM, Somers, USA). Attack rates (ARs) and incidence rates (IRs)
were based on positive anti-circumsporozoite antibody serocon-
version indicative for exposure to P. falciparum. ARs were
calculated by dividing the number of study subjects displaying
seroconversion in the CSP-ELISA by the total number of
participants at risk. IRs per 100 person-months were calculated
by dividing the number of travelers with exposure to P. falciparum
by our calculation of their exposure time. If a traveler was exposed
to P. falciparum, we used half of their travel duration in endemic
area as their exposure time; for travelers without exposure to P.
falciparum, we used their total travel duration. Pearson chi-square
tests of association were used to compare categorical variables
between any two groups. Independent determinants for adherence
to chemoprophylaxis and for use of DEET were identified by
multiple logistic regression analysis and expressed as odds ratios
with 95% confidence intervals. A p-value ,0.05 was considered
statistically significant.
Results
Study Population
A total of 945 travelers to malaria-endemic countries were
recruited. Of these, 400 (42%) were male (Table 1). The majority
(616, 65%) was under 45 years of age, most (783, 83%) had visited
tropical or subtropical countries before, and 879 (93%) were born
in a Western country; 815 (86%) traveled for holiday; 71 (8%)
traveled for work or education, and 59 (6%) were VFR. More than
half (529, 56%) stayed less than 14 days in malaria-endemic areas.
The most frequently visited continent was Asia (454, 48%); 285
(30%) traveled to Africa and 206 (22%) to Latin America.
Of the 945 travelers, 620 (66%) were advised of both
chemoprophylaxis and preventive measures against mosquito
bites. The other 325 participants traveled to low-endemic areas.
Adherence to Chemoprophylaxis among Travelers to
High-endemic Areas
Of the 620 travelers to high-endemic areas who were prescribed
chemoprophylaxis, 449 were prescribed atovaquone-proguanil
(48%), 91 proguanil (10%), 70 mefloquine (8%), and 10 (2%) other
types of chemoprophylaxis, such as minocyclin, doxycycline, or a
combination of chemoprophylaxis.
Table 3. Adherence to the most-prescribed antimalarial chemoprophylaxis among travelers who started with recommended
chemoprophylaxis.
Advised Starteda
Prior to reaching
endemic area(s)b
While in endemic
area(s)c
After leaving endemic
area(s)d
N n1 n1/N n2 n2/n1 n3 n3/n1 n4 n4/n1
Mefloquine 70 69 99% 63 91% 68 99% 63 91%
Atovaquone-proguanil 449 396 88% 331 84% 374 94% 300 76%
Proguanil 91 76 84% NA NA 68 89% 56 74%
NA, not applicable.
doi:10.1371/journal.pone.0056863.t003
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Of 620 travelers, 520 (84%) took at least 75% of the
recommended tablets during their stay in high-endemic areas
(Table 2). In multivariable analysis, travelers to Africa were
significantly more adherent to chemoprophylaxis than travelers to
Asia or Latin America (OR 3.5 (95% CI 1.9–6.5) and 2.7 (95% CI
1.4–5.3) respectively); travelers who spent 14–29 days in endemic
areas were significantly more adherent compared to travelers who
spent either #13 days or $29 days in endemic areas (OR 2.2
(95% CI 1.2–3.8) and 2.5 (95% CI 1.1–5.6) respectively); travelers
who used DEET as an additional preventive measure in more than
50% of days spent in high-endemic areas were significantly more
adherent to chemoprophylaxis compared to those who did not use
DEET (OR 2.6 (95% CI 1.4–4.8)); and travelers using mefloquine
were significantly more adherent compared to travelers using
atovaquone-proguanil or proguanil (OR 5.3 (95% CI 1.2–23.1)
and 6.0 (95% CI 1.3–27.5) respectively); Of 620 travelers, 466
(75%) took 100% of the recommended advised tablets during their
stay in high-endemic areas, with the same determinants as for 75%
adherence.
Table 3 shows the adherence to mefloquine, atovaquone-
proguanil and proguanil prior to, during, and after stay in endemic
area(s) among travelers who started with prophylaxis. The highest
adherence percentage for all categories was found among travelers
using mefloquine.
Antimosquito Preventive Measures
Of 945 travelers, 791 (84%) used DEET, 465 (49%) used a
mosquito net, and 544 (58%) slept in an air-conditioned room at
least once.
Multivariable analysis showed that travelers born in a non-
Western country used significantly less DEET and also slept
significantly less often under a mosquito net than travelers born in
a Western country. Female travelers used significantly more
DEET than male travelers. Older travelers used significantly less
DEET or mosquito nets than younger travelers. Spending more
days in endemic areas was an independent determinant for using
less DEET and sleeping less often in an air-conditioned room.
Travelers to high-endemic areas in general used a mosquito net
significantly more often and slept less often in an air-conditioned
room compared to travelers to low-endemic areas. Travelers to
Africa or Latin America used a mosquito net significantly more
often and slept less often in an air-conditioned room compared to
travelers to Asia.
Anti-circumsporozoite Antibodies
Of 945 travelers, only 938 serum samples were tested using the
CSP-ELISA method because the sample was insufficient to test in
7 cases. Of the 938 samples, 4 (AR 0.4% (95% CI 0.1–1.0))
showed an anti-circumsporozoite antibody seroconversion. All 4
travelers were born in the Netherlands, had been 100% adherent
to their chemoprophylaxis during travel, and none reported fever
or had visited a doctor (Table 4). Of the 4 travelers, 2 stayed in a
high-endemic area up to 14 days and 2 between 14 and 29 days; 2
visited Africa, 1 India and 1 Suriname. The overall IR of anti-
circumsporozoite antibodies was 0.8 per 100 person-months (95%
CI 0.3–2.0).
Fever
Of the 945 travelers, 74 (8%) reported fever after a median
period of 17 days (IQR 12–26) in endemic areas. Of these 74,
67 (91%) used the provided thermometer and recorded fever
with a median temperature of 38.7uC (IQR 38.2uC–39.6uC). Of
the 74, 24 (32%) had visited low-endemic areas and 50 (68%)
high-endemic areas. Of 24 travelers who reported fever in low-
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endemic areas, 13 (54%) sought medical attention abroad, 2 of
whom were tested negative for malaria. Of 50 travelers to high-
endemic areas, 17 (34%) consulted a doctor abroad, of whom 8
were tested for malaria and 3 were actually treated for malaria.
These last 3 travelers had been fully adherent to chemopro-
phylaxis during travel and tested negative for anti-circumspor-
ozoite antibodies.
Discussion
In this prospective study with short-term travelers to malaria-
endemic countries, self reported adherence to chemoprophylaxis
was good. Best adherence was found among travelers to Africa,
travelers using mefloquine as chemoprophylaxis, travelers who
spent 14–29 days in endemic areas and travelers who were more
adherent to use of DEET. Based on seroconversions for anti-
circumsporozoite antibodies, we found an overall attack rate (AR)
for P. falciparum of 0.4% and an overall incidence rate (IR) of 0.8
per 100 person-months.
Adherence to chemoprophylaxis found in our study is in
agreement with self reported treatment adherence found in other
studies, which ranged from 70%–89% for atovaquone-proguanil
and 72%–95% for mefloquine [14,15,24,25]. Travelers to Africa
were more adherent to chemoprophylaxis, which is also consistent
with other studies [14,20,26]. Even though in our travel
consultation we do not communicate differences in risk between
different high-endemic continents, it is possible that travelers know
that malaria risk in Africa is higher than in other continents and
therefore are more cautious. This may also be the reason that
travelers to high-endemic areas used a mosquito net more often
than in other areas. Further, we found good adherence to DEET
to be independently related to good adherence to chemoprophy-
laxis, suggesting that those travelers who were more adherent to
one preventive measure were also more likely to follow other
preventive measures. These results are in agreement with previous
reports [27,28]. The high level of adherence to mefloquine in our
study suggests that this group of travelers experienced minimal
side effects, which is supported by data in the daily diaries. One
could argue that travelers who did not tolerate mefloquine during
previous travel due to side effects chose to use alternative
chemoprophylaxis, such as atovaquone-proguanil or doxycycline.
However, previous travel experience was univariably not associ-
ated with better adherence to mefloquine, atovaquone-proguanil,
or doxycycline.
As in our study, previous studies found longer travel duration to
be a determinant of nonadherence [24,29].
Determinants of nonadherence to chemoprophylaxis found in
previous studies were visiting friends and/or relatives (VFR),
younger age, extensive travel experience, adventurous travel, and
(assumed) adverse reactions [20,24,26,29,30]. We did not find
VFR to be less adherent than other groups of travelers. This is
probably because Lobel et al and Ropers et al studied travelers
flying back from destinations, whereas VFR in our study (only 7%
of the total study population) were recruited in a pretravel clinic
and are therefore not representative for VFR in general. The VFR
in our study were probably more aware of the risk, therefore
attended our pre-travel clinic and were also more likely to follow
our recommended chemoprophylaxis. Indeed, imported malaria is
mostly seen in VFR who did not seek pre-travel health advice and
who never intended to use chemoprophylaxis, or who used
chemoprophylaxis inadequately [4,31,32].
Furthermore, we did not find a relation between travel
experience and adherence, but we did find less adherence to
chemoprophylaxis in younger travelers, although not significantly.
Studies have shown that detecting anti-circumsporozoite
antibodies can be used in nonimmune travelers using chemopro-
phylaxis as a measure of P. falciparum infection [3,13,17,19,33,34].
In our study population, 0.4% had a recent infection with P.
falciparum sporozoites. All 4 travelers were infected in high-endemic
areas, none reported fever or malaria treatment, and all had been
adherent to chemoprophylaxis. This suggests that the use of
chemoprophylaxis protected these 4 travelers from clinical
malaria. There are a few other prospective studies on malaria
infection using anti-circumsporozoite antibody tests in nonim-
mune travelers using chemoprophylaxis [13,17,19]. The AR of
0.4% we found was lower than the AR found in 1991–1992 by
Cobelens et al (1.3%), but their IR of 1.7 per 100 person-months is
comparable to our IR (IR 0.8; 95% CI 0.3–2.0). Nothdurft et al
published in 1999 an AR of 4.96% and Knappik et al found in
1999 an AR of 0.95%. Differences in ARs could be due to changes
in incidences [8,35,36], but also to differences in group
characteristics, countries visited, or the use of different ELISA
tests. Therefore the studies cannot be compared.
Our study is one of the few comprehensive studies that
combined P. falciparum anti-circumsporozoite seroconversion,
adherence to chemoprophylaxis, and collection of clinical malaria
data among travelers. The prospective nature of this study with
blood samples pre- and post-travel allowed estimating the AR and
IR of exposure to P. falciparum malaria. The daily diary entries,
which minimized recall bias, provided a good record of the use of
chemoprophylaxis and antimosquito preventive measures, fever,
and treatment for malaria during travel.
Interpretation of our study results may be influenced by a
number of shortcomings. First, the daily diary entries could have
served as a reminder for travelers to take their chemoprophylaxis
and therefore lead to better adherence to treatment. Second,
because of the study design, the end date for travelers to fill in their
diaries was 2 weeks after return, so we do not know if travelers
using mefloquine or proguanil continued chemoprophylaxis after
the 2 weeks. Treatment adherence during stay in endemic areas,
however, remains most important in protection against infection
with P. falciparum. Finally, measurement of malaria exposure by
anti-CSP seroconversion has limitations due to the methodology.
The sensitivity is limited due to small numbers of inoculated
sporozoites by infected mosquitoes and their short life span [37].
Development of a detectable anti-CSP response is dose related and
requires multiple inoculations [34,38]. Preliminary data from
controlled human malaria infections in malaria naı¨ve Dutch
volunteers [39] show that anti-CSP seroconversion occurs in 30%
of the volunteers after a single infection with 5 infected mosquitoes
(Sauerwein, unpublished). Therefore, the actual number of
travelers exposed to sporozoites may be higher for all endemic
areas, and our AR and IR likely represent underestimations. The 3
seronegative travelers treated for malaria may have been exposed
and infected.
In conclusion, travel to Africa, using mefloquine, travel duration
of 14–29 days in endemic areas, and good adherence to DEET
were associated with good adherence to chemoprophylaxis.
Adherence to chemoprophylaxis in combination with other
preventive measures was good enough to protect the travelers
who seroconverted from clinical malaria. None of the travelers to
low-endemic areas where chemoprophylaxis is not recommended
contracted malaria, so there is no reason to adapt the Dutch
national guidelines. Similar prospective studies with larger
numbers to specific destinations are needed to make more specific
destination- dependent advice about the use of chemoprophylaxis.
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